Lumida
/CELC
⌘K
Celcuity Inc

Celcuity Inc

CELC
$88.38USD↑+0.10%+0.09 today

MARKET CAP

4.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$86 – $91

52W RANGE

$13
$151

AI Summary

Stalk
TrimMedium

CELC remains in a Stage 4 decline with a clear sequence of lower highs and lower lows reinforced by a bearish primary pattern. Medium-term bias is bearish, but near-term price is extended below declining EMAs and oversold, offering no optimal Sell Now setup. Execution is deferred: plan to Trim into any relief bounce into the 9/20 EMA and 50 DMA confluence for higher-probability entries.

  • ↑Phase III Victoria I trial reported 9.3-month median PFS for gadotelicib.
  • ↑FDA PDUFA date set for July 17, 2026; management sees no delay risk.
  • ↓Q1 2026 net loss rose to $52.8M vs $37M last year.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Salcuity, Inc. (NASDAQ: SLCY) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for advanced cancers, particularly targeting HR-positive, HER2-negative advanced breast cancer and metastatic castration-resistant prostate cancer. With its lead candidate, gadotelicib, the company aims to establish a new standard of care in oncology, engaging in pivotal clinical trials and potentially significant market dynamics as it approaches FDA approval.

Bull says

  • ↑Phase III Victoria I trial reported 9.3-month median PFS for gadotelicib.
  • ↑FDA PDUFA date set for July 17, 2026; management sees no delay risk.
  • ↑Estimated $5B TAM with up to $2.5B peak revenue opportunity.
  • ↑Subcutaneous gadotelicib could serve ~90K women annually, boosting uptake.
  • ↑$387M cash reserves fund operations through 2027 amid ongoing R&D.
  • ↑High dividend yield and growing institutional 13F stakes indicate investor interest.

Bear says

  • ↓Q1 2026 net loss rose to $52.8M vs $37M last year.
  • ↓Q1 operating cash burn hit $55.1M, stressing financial sustainability.
  • ↓R&D spending climbed to $33.1M, increasing cash burn trajectory.
  • ↓Competitive PI3K inhibitors heighten market share risk if approved.
  • ↓FDA approval uncertainty on July 17, 2026 exposes launch timing risk.
  • ↓Weak profitability metrics and leverage risk pressure valuation and returns.

Investment themes with CELC

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-15-2026bullish

Transcript signals

Bull points

  • We continue to make great progress as we prepare for the potential approval and commercial launch of Get It Solicit in the third quarter. Achieving these milestones would be a pivotal moment for the women with advanced breast cancer who need new therapeutic options.
  • And this offers the potential to advance the standard of care for the approximately 90,000 women each year who are newly diagnosed in the U.S. with HR-positive HER2-negative advanced breast cancer.
  • And these results confirm the role the PAM pathway plays in patients with or without PIK3CA mutations and the importance of multi-target inhibition of this pathway.

Bear points

  • Our first quarter net loss was $52.8 million, or $0.97 per share, compared to a net loss of $37 million, or $0.86 per share, for the first quarter of 2025.
  • Our non-GAAP adjusted net loss was $46.8 million, or $0.86 per share, for the first quarter of 2026 compared to non-GAAP adjusted net loss of $34.7 million or 81 cents per share for the first quarter of 2025.
  • Net cash used in operating activities for the first quarter of 2026 was $55.1 million compared to $35.9 million for the prior year period.
Read full transcript analysis ›